论文部分内容阅读
目的:探讨重组人干扰素α-2b凝胶联合外用溃疡散治疗合并人乳头瘤病毒(HPV)感染宫颈炎疗效。方法:76例HPV感染宫颈炎患者随机分为观察组36例和对照组40例。观察组给予重组人干扰素α-2b凝胶联合外用溃疡散;对照组仅给予外用溃疡散治疗。连续用药6个月后,比较两组患者HPV转阴情况,评定两组患者疗效,记录两组药品不良反应发生情况。结果:治疗后,观察组HPV转阴率83.33%,高于对照组的60.00%(P<0.001)。观察组总有效率88.89%,高于对照组的82.50%(P<0.05)。两组的不良反应发生情况差异无统计学意义。结论:重组人干扰素α-2b凝胶联合外用溃疡散对HPV感染宫颈炎临床疗效显著,值得临床推广应用。
Objective: To investigate the efficacy of recombinant human interferon α-2b gel combined with external ulcer powder in the treatment of cervicitis with human papillomavirus (HPV) infection. Methods: 76 cases of cervicitis with HPV infection were randomly divided into observation group 36 cases and control group 40 cases. The observation group was given recombinant human interferon α-2b gel combined with external ulcer powder; the control group was given only external ulcer powder treatment. Six months after continuous administration, HPV negative cases were compared between the two groups, and the curative effect of both groups was evaluated. The adverse reactions of two groups of drugs were recorded. Results: After treatment, the negative rate of HPV in the observation group was 83.33%, higher than that in the control group (60.00%, P <0.001). The total effective rate in observation group was 88.89%, which was higher than 82.50% in control group (P <0.05). There was no significant difference in adverse reactions between the two groups. Conclusion: The clinical efficacy of recombinant human interferon α-2b gel combined with external ulcer powder on HPV-infected cervicitis is significant and worthy of clinical application.